

Teleflex Incorporated

Q1 2021

Earnings Conference Call

Teleflex®

Conference Call Logistics

The release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on “Investors”)

Telephone replay is available by dialing (800) 585-8367 or for international calls, (416) 621-4642, conference ID 6194708

Today's Speakers

Liam Kelly

Chairman, President and CEO

Thomas Powell

Executive VP and CFO

Jake Elguicze

Treasurer and VP, Investor Relations

Note on Forward-Looking Statements

This presentation contains forward-looking statements, including, but not limited to, our expectations with respect to the 2021 national direct-to-consumer campaign related to the UroLift® System; our expectations with respect to the commercialization of, and a decision on reimbursement with respect to, the UroLift System in Japan; charges we expect to incur in connection with the restructuring program we commenced in the first quarter of 2021 (the "2021 restructuring program") and our other ongoing restructuring programs; estimated annualized pre-tax savings we expect to realize in connection with the 2021 restructuring program and our other ongoing restructuring programs and a similar initiative within our OEM segment (the "OEM initiative"); our expectations with respect to when we will begin to realize savings from the 2021 restructuring program, our other ongoing restructuring programs and the OEM initiative and when those programs will be substantially completed; our assumptions with respect to the euro to U.S. dollar exchange rate for 2021, our effective tax rate for 2021 and our adjusted weighted average shares for 2021; our forecasted 2021 GAAP and constant currency revenue growth, GAAP and adjusted gross and operating margins and GAAP and adjusted earnings per share and, in each case, the factors expected to impact those forecasted results; and other matters which inherently involve risks and uncertainties which could cause actual results to differ from those projected or implied in the forward–looking statements. These risks and uncertainties are addressed in our SEC filings, including our most recent Form 10-K. We expressly disclaim any obligation to update forward-looking statements, except as otherwise specifically stated by us or as required by law or regulation.

Note on Non-GAAP Financial Measures

This presentation refers to certain non-GAAP financial measures, including, but not limited to, constant currency revenue growth, adjusted diluted earnings per share, adjusted gross and operating margins and adjusted tax rate. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Tables reconciling these non-GAAP financial measures to the most comparable GAAP financial measures are contained within this presentation and the appendices at the end of this presentation.

Additional Notes

This document contains certain highlights with respect to our Q1 2020 performance and developments and does not purport to be a complete summary thereof. Accordingly, we encourage you to read our Earnings Release for the quarter ended March 28, 2021 located in the investor section of our website at www.teleflex.com and our Quarterly Report on Form 10-Q for the quarter ended March 28, 2021 to be filed with the Securities and Exchange Commission.

Unless otherwise noted, the following slides reflect continuing operations.

Executive Overview

Liam Kelly

Chairman, President and CEO

Teleflex®

Q1'21 Highlights

Q1 Performance Summary	• Q1'21 constant currency revenue growth showed continued sequential improvement on a day-sales adjusted basis • Q1'21 adjusted gross and operating margins expanded significantly year-over-year • Q1'21 adjusted earnings per share increased 5.5% as compared to the prior year period
Financial Guidance Update	• Raising 2021 as reported and constant currency revenue guidance ranges • Raising 2021 adjusted EPS guidance range

Q1'21 Financial Results

Revenue Highlights

- Q1'21 as reported revenue increased 0.5% versus Q1'20
- Q1'21 constant currency revenue declined 2.6% versus Q1'20
- Q1'21 constant currency growth adjusted for two-fewer selling days was modestly positive versus Q1'20

Global Product Revenue Drivers[1]

- Vascular Access revenue of $164.0 million, up 5.8% vs Q1'20, driven by sales of PICCs, CVCs and EZ-IO
- Anesthesia revenue of $84.9 million, up 7.0% vs Q1'20, driven by Z-Medica acquisition
- Interventional Urology revenue of $73.4 million, down 1.3% vs. Q1'20
    - Two fewer selling days was approximately a 3% headwind versus Q1'20

Adjusted Margin and Adjusted EPS Highlights

- Adjusted gross margin of 59.4%, up 210 bps versus 57.3% in prior year period
- Adjusted operating margin of 27.5%, up 190 bps versus 25.6% in prior year period
- Adjusted EPS of $2.87, up 5.5% versus $2.72 in the prior year period

1. All global product family revenue growth provided is on a constant currency basis

Note: Tables reconciling non-GAAP financial measures to the most comparable GAAP financial measures are included within this presentation and the appendices to this presentation.

Teleflex®

Q1'21 Segment Revenue Review

Dollars in Millions	Q1'21 Revenue	Q1'20 Revenue	Reported Revenue Growth	Currency Impact	Constant Currency Growth
Americas	$375.5	$358.0	4.9%	0.2%	4.7%
EMEA	$141.2	$156.1	(9.5)%	7.4%	(16.9)%
Asia	$63.7	$53.1	19.9%	9.6%	10.3%
OEM	$53.5	$63.4	(15.6)%	1.5%	(17.1)%
TOTAL	$633.9	$630.6	0.5%	3.1%	(2.6)%

Q1'21 Global Product Category Revenue Review

Dollars in Millions	Q1'21 Revenue	Q1'20 Revenue	Reported Revenue Growth	Currency Impact	Constant Currency Growth
Vascular Access	$164.0	$150.3	9.1%	3.3%	5.8%
Interventional	$96.2	$99.9	(3.8)%	2.6%	(6.4)%
Anesthesia	$84.9	$75.7	12.1%	5.1%	7.0%
Surgical	$80.4	$75.4	6.6%	4.3%	2.3%
Interventional Urology	$73.4	$74.2	(1.1)%	0.2%	(1.3)%
OEM	$53.5	$63.4	(15.6)%	1.5%	(17.1)%
Other[1]	$81.7	$91.7	(11.0)%	4.3%	(15.3)%
TOTAL	$633.9	$630.6	0.5%	3.1%	(2.6)%

1. Includes revenues generated from sales of the Company's respiratory and urology products (other than interventional urology products).

Clinical and Commercial Updates

Interventional Urology - UroLift® System

KEY TAKEAWAYS

Launched 2021 National DTC Campaign

- Investment expected to be slightly more than double the 2020 campaign amount
- Expect advertisements to be on air throughout most 2021
- Builds upon successful 2020 campaign that doubled brand awareness for targeted men w/ BPH
- Optimized existing network selection, testing new networks and programming

UroLift® 2 and UroLift® ATC Commercial Progress

- Controlled U.S. commercialization initiated, with positive clinician feedback
- Production capacity ramping to support demand

Japan Progress

- Japan commercialization remains on track, with reimbursement still expected in 2H 2021





Teleflex®

Clinical and Commercial Updates

Interventional - Manta® Vascular Closure Device

KEY TAKEAWAYS

MARVEL Registry

- Prospective real-world study of 500 patients who underwent transfemoral large bore percutaneous procedures in 10 hospitals across Europe and Canada
- Primary performance endpoint: 50 seconds median time from deployment to hemostasis
- Primary endpoint: MANTA use associated with a 4% VARC-2 major vascular complication rate, which closely matches the 4.2% VARC-2 major vascular complication rate demonstrated in the SAFE MANTA IDE clinical trial
- The SAFE trial applied more stringent inclusion/exclusion criteria, with a ~50% smaller sample size (n=263) compared to MARVEL. MARVEL therefore appears to confirm MANTA safety in a broader patient population and its feasibility in real world clinical practice.



Manta® Vascular Closure Device

Kroon, HG, Tonino, PAL, Savontaus, M, et al. Dedicated plug based closure for large bore access –The MARVEL prospective registry. Catheter Cardiovasc Interv. 2020; 1– 9. https://doi.org/10.1002/ccd.29439

Clinical and Commercial Updates

Interventional - Manta® Vascular Closure Device

KEY TAKEAWAYS

MANTA Meta-Analysis

- Patient-level pooled analysis including data from 2 medical device approval studies (CE mark, SAFE) and 1 post-approval registry (MARVEL), with large bore procedures performed by 71 operators at 28 investigational sites across North America and Europe from 2015 to 2019.
- Results:
  - Technical success rate: 96.4%
  - Hemostasis: 31 seconds median time from deployment to hemostasis
  - Low complication rates*: 4.4% major access complications and 4.7% minor access complication rates



Manta® Vascular Closure Device

*composite of MANTA related access site complications of which definitions were adapted from the derived from VARC-2 criteria

Nuis R, Wood D, Kroon H, van Wiechen M, et al. Frequency, impact and predictors of access complications with plug-based large-bore arteriotomy closure - A patient level meta-analysis. Cardiovasc Revasc Med. 2021 Feb 15; https://doi.org/10.1016/j.carrev.2021.02.017

Teleflex®

Financial Overview

Thomas Powell

Executive VP and CFO

Q1'21 Financial Review

Global revenue generation of $633.9 million

- Revenue increased 0.5% vs. prior year period on an as-reported basis
- Revenue decreased 2.6% vs. prior year period on a constant currency basis

Gross margin performance

- GAAP gross margin of 54.3%, up 140 bps vs. prior year period
- Adjusted gross margin of 59.4%, up 210 bps vs. prior year period

Operating margin performance

- GAAP operating margin of 16.3%, down 860 bps vs. prior year period
- Adjusted operating margin of 27.5%, up 190 bps vs. prior year period

Effective tax rate

- GAAP tax rate of 14.2%, compared to 7.8% in prior year period
- Adjusted tax rate of 13.9%, up 140 bps vs. prior year period

Earnings per share

- GAAP EPS of $1.58 vs. $2.78 in prior year period
- Adjusted EPS of $2.87, up 5.5% vs. prior year period

Note: See appendices for reconciliations of non-GAAP information

2021 Financial Guidance Summary Slide

	Updated 2021 Guidance		Initial 2021 Guidance	
	Low	High	Low	High
GAAP Revenue Growth	**10.5%**	**11.75%**	**10.0%**	**11.5%**
Impact of Foreign Exchange Rate Fluctuations	**2.0%**	**2.0%**	**2.0%**	**2.0%**
Constant Currency Revenue Growth	**8.5%**	**9.75%**	**8.0%**	**9.5%**
Adjusted Gross Margin	58.25%	59.25%	58.0%	59.0%
Adjusted Operating Margin	26.0%	27.0%	26.0%	27.0%
Adjusted EPS	$12.65	$12.85	$12.50	$12.70
Adjusted EPS % Growth	18.6%	20.4%	17.2%	19.0%

Key Takeaways

- **Teleflex exceeded the externally provided first quarter 2021 revenue and adjusted earnings per share expectations provided in February**
- **Announced new restructuring program and remain on track to generate significant long term margin expansion**
- **Raised as reported and constant currency revenue guidance ranges, and adjusted EPS guidance range, given year-to-date performance and outlook for remainder of the year**





THANK YOU

Teleflex®

Appendices

Non-GAAP Financial Measures

The presentation to which these appendices are attached and the following appendices include, among other things, tables reconciling the following applicable non-GAAP financial measures to the most comparable GAAP financial measure:

- ***Constant currency revenue growth*.** This non-GAAP measure is based upon net revenues, adjusted to eliminate the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. The impact of changes in foreign currency may vary significantly from period to period, and generally are outside of the control of our management. We believe that this measure facilitates a comparison of our operating performance exclusive of currency exchange rate fluctuations that do not reflect our underlying performance or business trends.
- ***Adjusted diluted earnings per share*.** This non-GAAP measure is based upon diluted earnings per share from continuing operations, the most directly comparable GAAP measure, adjusted to exclude, depending on the period presented, the impact of (i) restructuring, restructuring related and impairment items; (ii) acquisition, integration and divestiture related items; (iii) "other items" identified in note (C) to the reconciliation tables appearing in Appendices D and E; (iv) certain costs associated with the registration of medical devices under the European Union Medical Device Regulation; (v) intangible amortization expense; and (vi) tax adjustments. Management does not believe that any of the excluded items are indicative of our underlying core performance or business trends.
- ***Adjusted gross profit and margin*.** These measures exclude, depending on the period presented, the impact of (i) restructuring, restructuring related and impairment items, (ii) acquisition, integration and divestiture related items and (iii) "other items" identified in note (C) to the reconciliation table appearing in Appendix A.
- ***Adjusted operating profit and margin*.** These measures exclude, depending on the period presented, the impact of (i) restructuring, restructuring related and impairment items; (ii) acquisitions, integration and divestiture related items; (iii) "other items" identified in note (C) to the reconciliation table appearing in Appendix B; (iv) intangible amortization expense; and (v) certain costs associated with the registration of medical devices under the European Union Medical Device Regulation.
- ***Adjusted tax rate*.** This measure is the percentage of the Company's adjusted taxes on income from continuing operations to its adjusted income from continuing operations before taxes. Adjusted taxes on income from continuing operations excludes, depending on the period presented, the impact of tax benefits or costs associated with (i) restructuring, restructuring related and impairment items; (ii) acquisition, integration and divestiture related items; (iii) "other items" identified in note (A) to the reconciliation table appearing in Appendix C; (iv) certain costs associated with the registration of medical devices under the European Union Medical Device Regulation; (v) intangible amortization expense; and (vi) tax adjustments.

Non-GAAP Adjustments

The following is an explanation of certain of the adjustments that are applied with respect to one or more of the non-GAAP financial measures that appear in the presentation to which these appendices are attached:

Restructuring, restructuring related and impairment items - Restructuring programs involve discrete initiatives designed to, among other things, consolidate or relocate manufacturing, administrative and other facilities, outsource distribution operations, improve operating efficiencies and integrate acquired businesses. Depending on the specific restructuring program involved, our restructuring charges may include employee termination, contract termination, facility closure, employee relocation, equipment relocation, outplacement and other exit costs associated with the restructuring program. Restructuring related charges are directly related to our restructuring programs and consist of facility consolidation costs, including accelerated depreciation expense related to facility closures, costs to transfer manufacturing operations between locations, and retention bonuses offered to certain employees as an incentive for them to remain with our company after completion of the restructuring program. Impairment charges occur if, due to events or changes in circumstances, we determine that the carrying value of an asset exceeds its fair value. Impairment charges do not directly affect our liquidity, but could have a material adverse effect on our reported financial results.

Acquisition, integration and divestiture related items - Acquisition and integration expenses are incremental charges, other than restructuring or restructuring related expenses, that are directly related to specific business or asset acquisition transactions. These charges may include, among other things, professional, consulting and other fees; systems integration costs; legal entity restructuring expense; inventory step-up amortization (amortization, through cost of goods sold, of the increase in fair value of inventory resulting from a fair value calculation as of the acquisition date); fair value adjustments to contingent consideration liabilities; and bridge loan facility and backstop financing fees in connection with loan facilities that ultimately were not utilized. Divestiture related activities involve specific business or asset sales. Depending primarily on the terms of a divestiture transaction, the carrying value of the divested business or assets on our financial statements and other costs we incur as a direct result of the divestiture transaction, we may recognize a gain or loss in connection with the divestiture related activities.

Other items - These are discrete items that occur sporadically and can affect period-to-period comparisons. See footnote C to the reconciliation tables set forth below.

European medical device regulation - The European Union (“EU”) has adopted the EU Medical Device Regulation (“MDR”), which replaces the existing Medical Devices Directive (“MDD”) and imposes more stringent requirements for the marketing and sale of medical devices in the EU, including requirements affecting clinical evaluations, quality systems and post-market surveillance. Manufacturers of currently marketed medical devices will have until May 2020 to meet the MDR requirements, although certain devices that previously satisfied MDD requirements can continue to be placed on the EU market until May 2024, subject to certain limitations. Significantly, the MDR will require the re-registration of previously approved medical devices. As a result, Teleflex will incur expenditures in connection with the new registration of medical devices that previously had been registered under the MDD. Therefore, these expenditures are not considered to be ordinary course expenditures in connection with regulatory matters (in contrast, no adjustment has been made to exclude expenditures related to the registration of medical devices that were not registered previously under the MDD).

Intangible amortization expense - Certain intangible assets, including customer relationships, intellectual property, distribution rights, trade names and non-competition agreements, initially are recorded at historical cost and then amortized over their respective estimated useful lives. The amount of such amortization can vary from period to period as a result of, among other things, business or asset acquisitions or dispositions.

Tax adjustments - These adjustments represent the impact of the expiration of applicable statutes of limitations for prior year returns, the resolution of audits, the filing of amended returns with respect to prior tax years and/or tax law or certain other discrete changes affecting our deferred tax liability.

Appendix A – Reconciliation of Adjusted Gross and Operating Margin, Income Tax and EPS (Dollars in millions, except per share data)

Three Months Ended March 28, 2021

	Gross Margin	Operating Margin	Income Before Income Taxes	Income Tax Expense	Income Tax Rate	Diluted Earnings Per Share
GAAP Basis	54.3 %	16.3 %	$ 87.3	$ 12.4	14.2 %	$ 1.58
Adjustments						
Restructuring, restructuring related and impairment items (A)	1.0 %	2.3 %	14.6	2.1		0.26
Acquisition, integration and divestiture related items (B)	0.5 %	1.6 %	10.1	1.1		0.19
Other items (C)	— %	— %	—	—		—
MDR (D)	— %	0.7 %	4.2	—		0.09
Intangible amortization expense	3.5 %	6.6 %	41.9	7.0		0.74
Tax adjustments	— %	— %	—	(0.6)		0.01
Adjustments total	5.1 %	11.2 %	70.8	9.6		1.29
Adjusted basis	**59.4 %**	**27.5 %**	**$ 158.1**	**$ 22.0**	**13.9 %**	**$ 2.87**

Three Months Ended March 29, 2020

	Gross Margin	Operating Margin	Income Before Income Taxes	Income Tax Expense	Income Tax Rate	Diluted Earnings Per Share
GAAP Basis	52.9 %	24.9 %	$ 142.2	$ 11.1	7.8 %	$ 2.78
Adjustments						
Restructuring, restructuring related and impairment items (A)	0.8 %	1.0 %	6.4	0.8		0.12
Acquisition, integration and divestiture related items (B)	0.3 %	(6.8)%	(42.6)	0.4		(0.91)
Other items (C)	— %	— %	—			—
MDR (D)	— %	0.3 %	1.8	—		0.04
Intangible amortization expense	3.3 %	6.2 %	38.9	6.2		0.69
Tax adjustments	— %	— %		(0.1)		—
Adjustments total	4.4 %	0.7 %	4.5	7.3		(0.06)
Adjusted basis	**57.3 %**	**25.6 %**	**$ 146.8**	**$ 18.4**	**12.5 %**	**$ 2.72**

See slide titled Non-GAAP Adjustments included at the beginning of the appendices to this presentation for Non-GAAP definitions.

Teleflex®

Appendix A tickmarks

A. **Restructuring, restructuring related and impairment items –** For the three months ended March 28, 2021, pre-tax restructuring charges were $8.0 million, pre-tax restructuring related charges were $6.6 million, and pre-tax impairment charges were $0.0 million. For the three months ended March 29, 2020, pre-tax restructuring charges were $1.3 million, pre-tax restructuring related charges were $5.1 million, and pre-tax impairment charges were $0.0 million.

B. **Acquisition, integration and divestiture related items –** For the three months ended March 28, 2021, these charges primarily related to contingent consideration liabilities; and the reversal of previously recognized income related to a distributor conversion in Japan; and charges primarily related to our acquisition of Z-Medica, LLC. For the three months ended March 29, 2020, these items primarily related to the reversal of contingent consideration liabilities; and changes related to our acquisition of IWG High Performance Conductors, Inc. There were no divestiture related activities for the three months ended March 28, 2021 and March 29, 2020.

C. **Other items –** For the three months ended March 28, 2021 and March 29, 2020, there were no adjustments made for other items.

D. **MDR –** These costs were associated with our efforts to comply with the European Medical Device Regulation (MDR).

See slide titled Non-GAAP Adjustments included at the beginning of the appendices to this presentation for Non-GAAP definitions.

Appendix B – Restructuring and Similar Cost Savings Initiatives Summary

2021 Restructuring plan

During the first quarter of 2021, we committed to a restructuring plan designed to streamline various business functions and consolidate manufacturing operations. We estimate that we will incur aggregate pre-tax restructuring charges of $7 million to $9 million, consisting primarily of termination benefits, and $3 million to $4 million in restructuring related charges. Most of restructuring related charges are expected to be recognized in cost of sales and primarily consist of project management costs, costs to transfer of manufacturing operations to existing lower-cost locations and accelerated depreciation. We expect this program will be substantially completed by the end of 2021.

As of March 28, 2021, we had a restructuring reserve of $6.4 million related to this plan, all of which related to termination benefits. We expect to begin realizing plan-related savings in 2021 and expect to achieve annual pre-tax savings of $13 million to $16 million once the plan is fully implemented.

In addition to the 2021 Restructuring plan, we have ongoing restructuring programs primarily related to the consolidation of our manufacturing operations (referred to as our 2019, 2018 and 2014 Footprint realignment plans). We also have similar ongoing activities to relocate certain manufacturing operations within our OEM segment (the "OEM initiative") that do not meet the criteria for a restructuring program under applicable accounting guidance; nevertheless, the activities should result in cost savings (we expect only minimal costs to be incurred in connection with the OEM initiative). With respect to our currently ongoing restructuring programs (including the 2021 Restructuring plan) and the OEM initiative, the table below summarizes charges incurred or estimated to be incurred and estimated annual pre-tax savings to be realized as follows: (1) with respect to charges (a) the estimated total charges that will have been incurred once the restructuring programs and OEM initiative are completed; (b) the charges incurred through December 31, 2020; and (c) the estimated charges to be incurred from January 1, 2021 through the last anticipated completion date of the restructuring programs and OEM initiative, and (2) with respect to estimated annual pre-tax savings, (a) the estimated total annual pre-tax savings to be realized once the restructuring programs and OEM initiative are completed; (b) the estimated annual pre-tax savings realized based on the progress of the restructuring programs and OEM initiative through December 31, 2020; and (c) the estimated additional annual pre-tax savings to be realized from January 1, 2021 through the last anticipated completion date of the restructuring programs and the OEM initiative.

Estimated charges and pre-tax savings are subject to change based on, among other things, the nature and timing of restructuring activities and similar activities, changes in the scope of restructuring programs and the OEM initiative, unanticipated expenditures and other developments, the effect of additional acquisitions or dispositions, and other factors that were not reflected in the assumptions made by management in previously estimating restructuring and restructuring related charges and estimated pre-tax savings. Moreover, estimated pre-tax savings constituting efficiencies with respect to increased costs that otherwise would have resulted from business acquisitions involve, among other things, assumptions regarding the cost structure and integration of businesses that previously were not administered by our management, which are subject to a particularly high degree of risk and uncertainty. It is likely that estimates of charges and pre-tax savings will change from time to time, and the table below may reflect changes from amounts previously estimated. In addition, the table below reflects the estimated charges and pre-tax savings related to our ongoing programs. Additional details, including estimated charges expected to be incurred in connection with our restructuring programs and the anticipated completion dates, are described in Note 5 to the condensed consolidated financial statements included in this report.

Dollars in Millions	Estimated Total	Actual results through December 31, 2020	Estimated Amount Remaining
Restructuring charges	$102 - $118	$89	$13 - $29
Restructuring related charges[1]	119 - 146	74	45 - 72
Total charges	**$221-$264**	**$163**	**$58 - $101**
OEM initiative annual pre-tax savings	$6 - $7	$2	$4 - $5
Pre-tax savings – ongoing restructuring plans[2]	81 - 94	32	49 - 62
Total annual pre-tax savings	**$87 - $101**	**$34**	**$53 - $67**

Appendix B – Footnotes

(1) Represents charges that are directly related to restructuring programs and principally constitute costs to transfer manufacturing operations to existing lower-cost locations, project management costs and accelerated depreciation, as well as a charge that is expected to be imposed by a taxing authority as a result of our exit from facilities in the authority's jurisdiction. Most of these charges (other than the tax charge) are expected to be recognized as cost of goods sold.

(2) Most of the pre-tax savings are expected to result in reductions to cost of goods sold.

Appendix C – March 28, 2021 Year-to-Date GPO and IDN Review

Group Purchasing Organization Update

	Q1'21
Renewed agreements	6
New agreements	1
Existing agreements lost	1

IDN Update

	Q1'21
Renewed agreements	13
New agreements	7
Existing agreements lost	0

Appendix D - 2021 Adj. Gross and Operating Margin Guidance Reconciliations

2021 Guidance	Low	High
Forecasted GAAP Gross Margin	53.95%	55.10%
Estimated restructuring, restructuring related and impairment items	0.95%	0.90%
Estimated acquisition, integration, and divestiture related items	0.15%	0.10%
Estimated other items	-	-
Estimated intangible amortization expense	3.20%	3.15%
Forecasted Adjusted Gross Margin	**58.25%**	**59.25%**

2021 Guidance	Low	High
Forecasted GAAP Operating Margin	17.00%	18.20%
Estimated restructuring, restructuring related and impairment items	1.40%	1.35%
Estimated acquisition, integration, and divestiture related items	0.65%	0.60%
Estimated other items	-	-
Estimated MDR	0.85%	0.80%
Estimated intangible amortization expense	6.10%	6.05%
Forecasted Adjusted Operating Margin	**26.00%**	**27.00%**

Appendix E – Reconciliation of 2021 Adjusted Earnings Per Share Guidance

2021 Guidance	Low	High
Forecasted GAAP Diluted Earnings Per Share from continuing operations	**$8.00**	**$8.10**
Estimated restructuring, restructuring related and impairment items, net of tax	$0.71	$0.72
Estimated acquisition, integration, and divestiture related items, net of tax	$0.30	$0.32
Estimated other items, net of tax	$0.17	$0.19
Estimated MDR, net of tax	$0.48	$0.50
Estimated intangible amortization expense, net of tax	$2.99	$3.02
Forecasted Adjusted Diluted Earnings Per Share from continuing operations	**$12.65**	**$12.85**

Appendix F – Key Assumptions for 2021 Financial Guidance

Outlook Includes:

- Due to COVID-19 resurgences globally, we continue to expect modest disruption to continue during 1H, and expect marked improvement moving throughout 2021
- Q2 growth should be partly driven by relatively easy year-over-year comparisons
- Health care systems are better equipped to deal with surges, thus, we do not expect any major systemic shutdown of elective procedures
- Euro to U.S. Dollar exchange rate assumed to be approximately 1.21 for full year 2021
- Adjusted weighted average shares expected to be approximately 47.7 million for full year 2021

Outlook Excludes:

- Any potential benefit from a substantial surge in COVID-related buying
- Material regulatory, healthcare, or U.S. tax reforms
- Future M&A opportunities

2021 Shipping days differentials:

- Q1’21 vs. Q1’20: 2 less days
- Q4’21 vs. Q4’20: 1 additional day
- FY’21 vs. FY’20: 1 less day
- FY'21 vs. FY'19: same number of days